Cancer pathogenesis and therapy最新文献

{"title":"Self-healing hydrogels for enhancing chemotherapy drug efficacy: Advancements in anti-sarcoma and carcinoma therapies and clinical trial feasibility","authors":"Luc Taylor","doi":"10.1016/j.cpt.2024.01.003","DOIUrl":"10.1016/j.cpt.2024.01.003","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 2","pages":"Pages 132-134"},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S294971322400003X/pdfft?md5=c9dc48e0e740212a721e1e467a958e1d&pid=1-s2.0-S294971322400003X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139878892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autophagy as a targeted therapeutic approach for skin cancer: Evaluating natural and synthetic molecular interventions","authors":"Md. Liakot Ali ,&nbsp;Amdad Hossain Roky ,&nbsp;S.M. Asadul Karim Azad ,&nbsp;Abdul Halim Shaikat ,&nbsp;Jannatul Naima Meem ,&nbsp;Emtiajul Hoque ,&nbsp;Abu Mohammed Fuad Ahasan ,&nbsp;Mohammed Murshedul Islam ,&nbsp;Md. Saifur Rahaman Arif ,&nbsp;Md. Saqline Mostaq ,&nbsp;Md. Zihad Mahmud ,&nbsp;Mohammad Nurul Amin ,&nbsp;Md. Ashiq Mahmud","doi":"10.1016/j.cpt.2024.01.002","DOIUrl":"10.1016/j.cpt.2024.01.002","url":null,"abstract":"<div><div>Skin cancer, a prevalent malignancy worldwide, poses significant health concerns owing to its increasing incidence. Autophagy, a natural cellular process, is a pivotal event in skin cancer and has advantageous and detrimental effects. This duality has prompted extensive investigations into medical interventions targeting autophagy modulation for their substantial therapeutic potential. This systematic review aimed to investigate the relationship between skin cancer and autophagy and the contribution and mechanism of autophagy modulators in skin cancer. We outlined the effectiveness and safety of targeting autophagy as a promising therapeutic strategy for the treatment of skin cancer. This comprehensive review identified a diverse array of autophagy modulators with promising potential for the treatment of skin cancer. Each of these compounds demonstrates efficacy through distinct physiological mechanisms that have been elucidated in detail. Interestingly, findings from a literature search indicated that none of the natural, synthetic, or semisynthetic compounds exhibited notable adverse effects in either human or animal models. Consequently, this review offers novel mechanistic and therapeutic perspectives on the targeted modulation of autophagy in skin cancer.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 4","pages":"Pages 231-245"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713224000028/pdfft?md5=49e34dccae0c252025870fda72f8c316&pid=1-s2.0-S2949713224000028-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial","authors":"Nan Jin ,&nbsp;Yi Xu ,&nbsp;Siqi Wang ,&nbsp;Chunxiao Sun ,&nbsp;Xueqi Yan ,&nbsp;Fan Yang ,&nbsp;Yan Liang ,&nbsp;Weiwei Chen ,&nbsp;Xiang Huang","doi":"10.1016/j.cpt.2023.10.004","DOIUrl":"10.1016/j.cpt.2023.10.004","url":null,"abstract":"<div><h3>Background</h3><p>Human epidermal growth factor receptor 2 (HER2)-targeted agents have significantly improved the outcomes of patients with HER2-positive breast cancer; however, a large proportion of patients still develop resistance to trastuzumab. In this study, we investigated the efficacy and safety of inetetamab, another anti-HER2 antibody, combined with pyrotinib and oral vinorelbine in patients with HER2-positive advanced breast cancer so as to provide new ideas for the treatment.</p></div><div><h3>Methods</h3><p>In this prospective, single-arm, phase 2 trial, patients with HER2-positive advanced breast cancer with disease progression after trastuzumab were recruited. Patients received a combination of inetetamab (loading dose of 8 mg/kg and subsequent doses of 6 mg/kg intravenously once every 3 weeks), pyrotinib (400 mg orally once daily), and vinorelbine (60 mg/m² orally once weekly) until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), overall survival (OS), disease control rate (DCR), and safety.</p></div><div><h3>Results</h3><p>Between February 13, 2022 and December 25, 2022, 30 patients were screened and enrolled in this study. The median age of the patients at enrollment was 54 years, 12 patients (40.0 %) had hormone-receptor-positive disease and 23 patients (76.7 %) had visceral metastasis. The median PFS was 8.63 months (95 % confidence interval [CI] 4.15–13.12 months). The median OS was not reached. The ORR was 53.3 % (16/30) and the DCR was 96.7 % (29/30). The most common Grade III/IV adverse events were leukopenia (<em>n</em> = 5, 16.7 %), neutropenia (<em>n</em> = 4, 13.3 %), and diarrhea (<em>n</em> = 3, 10 %). No treatment-related serious adverse events or deaths occurred.</p></div><div><h3>Conclusions</h3><p>The combination regimen of inetetamab, pyrotinib, and oral vinorelbine showed encouraging efficacy and favorable safety in patients with HER2-positive advanced breast cancer and could be considered as an alternative treatment option for the patients.</p></div><div><h3>Trial registration</h3><p>No.NCT05823623; <span>https://www.clinicaltrials.gov/</span><svg><path></path></svg>.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 1","pages":"Pages 31-37"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000861/pdfft?md5=dc961df2356f92d5808448e7ca98f6ad&pid=1-s2.0-S2949713223000861-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136128019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover","authors":"","doi":"10.1016/S2949-7132(23)00099-X","DOIUrl":"https://doi.org/10.1016/S2949-7132(23)00099-X","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 1","pages":"Page OFC"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S294971322300099X/pdfft?md5=4c7f38dde2dfdc0238657791fc9e10bf&pid=1-s2.0-S294971322300099X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139108108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone metastasis is a late-onset and unfavorable event in survivors of gastric cancer after radical gastrectomy: Results from a clinical observational cohort","authors":"Cheng Zhang ,&nbsp;Xiaopeng Zhang ,&nbsp;Chong Feng ,&nbsp;Yahui Yang ,&nbsp;Minmin Xie ,&nbsp;Ying Feng ,&nbsp;Zhijun Wu ,&nbsp;Hui Xu ,&nbsp;Changhao Wu ,&nbsp;Tai Ma","doi":"10.1016/j.cpt.2023.11.003","DOIUrl":"10.1016/j.cpt.2023.11.003","url":null,"abstract":"<div><h3>Background</h3><p>The timing and incidence of recurrent bone metastasis (BM) after radical gastrectomy in patients with gastric cancer (GC) as well as the survival of these patients were not fully understood. The aim of this study was to analyze the data of an observational GC cohort and identify patients who underwent curative gastrectomy and had recurrent BM to describe and clarify the pattern and profile of BM evolution after surgery.</p></div><div><h3>Methods</h3><p>Data were retrieved from a hospital-based GC cohort, and patients who underwent upfront radical gastrectomy were selected. The time points of specific organ metastatic events were recorded, and the person-year incidence rate of metastatic events was calculated. The latency period of BM events after gastrectomy was measured and compared with that of the other two most common metastatic events, liver metastasis (LM) and distant lymph node metastasis (LNM), using analysis of variance. Propensity score matching and subgroup analysis were used for sensitivity analysis.</p></div><div><h3>Results</h3><p>A total of 1324 GC cases underwent radical gastrectomy between January 2011 and December 2021. Of these, 67 BM, 218 LM, and 248 LNM occurred before the last follow-up. The incidence of BM events was 1.7/100 person-years, which was approximately 3-fold lower than that of LM and distant LNM events (5.5 and 6.3 per 100 person-years, respectively). BM events had a significantly longer latency (median time, 16.5 months) than LM and LNM events (11.1 and 12.0 months, respectively). Recurrent BM led to a worse prognosis (median survival, 4.5 months) than those of LM and LNM events (median survival, 7.7 and 7.1 months, respectively). However, no difference in overall survival after gastrectomy was observed among the groups.</p></div><div><h3>Conclusions</h3><p>Compared with other common metastatic events, BM in GC after gastrectomy is a late-onset event indicating poor survival.</p></div><div><h3>Trial registration</h3><p>No. ChiCTR1800019978; <span>http://www.chictr.org.cn/</span><svg><path></path></svg>.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 1","pages":"Pages 50-57"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000927/pdfft?md5=44a805ff0115c91ffd88551b42f13026&pid=1-s2.0-S2949713223000927-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135763761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two cases on primary bone marrow lymphoma","authors":"Zining Wang ,&nbsp;Lu Sun ,&nbsp;Yue Wang ,&nbsp;Haoran Chen ,&nbsp;Hongbin Pu ,&nbsp;Bo Yang ,&nbsp;Xuechun Lu","doi":"10.1016/j.cpt.2023.10.001","DOIUrl":"10.1016/j.cpt.2023.10.001","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 1","pages":"Pages 58-61"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000836/pdfft?md5=ec1083df58b222e3247b5e3235119349&pid=1-s2.0-S2949713223000836-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135605570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experimental models for cancer brain metastasis","authors":"Zihao Liu ,&nbsp;Shanshan Dong ,&nbsp;Mengjie Liu ,&nbsp;Yuqiang Liu ,&nbsp;Zhiming Ye ,&nbsp;Jianhao Zeng ,&nbsp;Maojin Yao","doi":"10.1016/j.cpt.2023.10.005","DOIUrl":"10.1016/j.cpt.2023.10.005","url":null,"abstract":"<div><p>Brain metastases are a leading cause of cancer-related mortality. However, progress in their treatment has been limited over the past decade, due to an incomplete understanding of the underlying biological mechanisms. Employing accurate <em>in vitro</em> and <em>in vivo</em> models to recapitulate the complexities of brain metastasis offers the most promising approach to unravel the intricate cellular and physiological processes involved. Here, we present a comprehensive review of the currently accessible models for studying brain metastasis. We introduce a diverse array of <em>in vitro</em> and <em>in vivo</em> models, including cultured cells using the Transwell system, organoids, microfluidic models, syngeneic models, xenograft models, and genetically engineered models. We have also provided a concise summary of the merits and limitations inherent to each model while identifying the optimal contexts for their effective utilization. This review serves as a comprehensive resource, aiding researchers in making well-informed decisions regarding model selection that align with specific research questions.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 1","pages":"Pages 15-23"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000873/pdfft?md5=815b1f0ff05fad760d1811a05b60dfc1&pid=1-s2.0-S2949713223000873-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136152804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors","authors":"Chuandong Hou ,&nbsp;Zining Wang ,&nbsp;Xuechun Lu","doi":"10.1016/j.cpt.2023.08.001","DOIUrl":"10.1016/j.cpt.2023.08.001","url":null,"abstract":"<div><p>Immune checkpoint inhibitors (ICIs) are employed in immunotherapeutic applications for patients with weakened immune systems and can improve the ability of T cells to kill cancer cells. Although ICIs can potentially treat different types of cancers in various groups of patients, their effectiveness may differ among older individuals. The reason ICIs are less effective in older adults is not yet clearly understood, but age-related changes in the immune system, such as immunosenescence and inflammation, may play a role. Therefore, this review focuses on recent advances in understanding the effects of immunosenescence and inflammation on the efficacy of ICIs.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 1","pages":"Pages 24-30"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000484/pdfft?md5=de94deaec420e00e46c23da7252d8e24&pid=1-s2.0-S2949713223000484-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82353641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preimplantation genetic testing for embryos predisposed to hereditary cancer: Possibilities and challenges","authors":"Mohammed H. Albujja ,&nbsp;Maher Al-Ghedan ,&nbsp;Lakshmidevi Dakshnamoorthy ,&nbsp;Josep Pla Victori","doi":"10.1016/j.cpt.2023.05.002","DOIUrl":"10.1016/j.cpt.2023.05.002","url":null,"abstract":"<div><p>Preimplantation genetic testing (PGT), which was developed as an alternative to prenatal genetic testing, allows couples to avoid pregnancies with abnormal chromosomes and the subsequent termination of the affected fetus. Originally used for early onset monogenic conditions, PGT is now used to prevent various types of inherited cancer conditions based on the development of PGT technology, assisted reproductive techniques (ARTs), and <em>in vitro</em> fertilization (IVF). This review provides insights into the potential benefits and challenges associated with the application of PGT for hereditary cancer and provides an overview of the existing literature on this test, with a particular focus on the current challenges related to laws, ethics, counseling, and technology. Additionally, this review predicts the future potential applications of this method. Although PGT may be utilized to predict and prevent hereditary cancer, each case should be comprehensively evaluated. The motives of couples must be assessed to prevent the misuse of this technique for eugenic purposes, and non-pathogenic phenotypes must be carefully evaluated. Pathological cases that require this technology should also be carefully considered based on legal and ethical reasoning. PGT may be the preferred treatment for hereditary cancer cases; however, such cases require careful case-by-case evaluations. Therefore, this study concludes that multidisciplinary counseling and support for patients and their families are essential to ensure that PGT is a viable option that meets all legal and ethical concerns.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 1","pages":"Pages 1-14"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000265/pdfft?md5=664fbd9bca1e903ebc7ed8bf7ce4bd1c&pid=1-s2.0-S2949713223000265-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81330991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial note to previously published articles","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 4","pages":"Page 321"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000563/pdfft?md5=23362d3c2e3531332b15e418446a4d96&pid=1-s2.0-S2949713223000563-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}